Codeine crackdown could cost $1.27 billion over four years… and more

Upscheduling codeine-containing OTCs could cost upwards of $1.27 billion in MBS outlay alone over the next four years, a new report has found. The Pharmacy Guild engaged Cadence Economics to undertake an analysis of the fiscal impacts of upscheduling all medicines containing codeine to prescription only. Currently there are 16.4 million units sold each year